Skip to content

4527.T

ROHTO PHARMACEUTICAL CO.,LTD.

プライム · 医薬品 · 医薬品 · JP

JPY 3,057.00
+0.59%
Ask drillr

Year over year

Reported trailing growth

Revenue
+11.4%
EBITDA
EBIT
+5.6%
EPS
+11.5%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
-0.9%
EBITDA
EPS
-3.6%

Three-year CAGR

Revenue
+12.9%
EBITDA
+10.9%
EBIT
+6.6%
Net income
+9.1%
EPS
+9.4%
Free cash flow
+17.4%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026